184 related articles for article (PubMed ID: 15115188)
1. Erectile dysfunction and cardiovascular considerations: managing patients effectively with phosphodiesterase type 5 inhibitors.
Hutter AM
Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I1-2. PubMed ID: 15115188
[No Abstract] [Full Text] [Related]
2. [Phosphodiesterase-5 inhibitor with broad temporal effectiveness window].
MMW Fortschr Med; 2004 Apr; 146(16):62. PubMed ID: 15222506
[No Abstract] [Full Text] [Related]
3. Treating erectile dysfunction by endothelial rehabilitation with phosphodiesterase 5 inhibitors.
Sommer F; Schulze W
World J Urol; 2005 Dec; 23(6):385-92. PubMed ID: 16273418
[TBL] [Abstract][Full Text] [Related]
4. PDE5 inhibitors: looking beyond ED.
Jackson G
Int J Clin Pract; 2003 Apr; 57(3):159-60. PubMed ID: 12723713
[No Abstract] [Full Text] [Related]
5. Molecular biology and pharmacology of PDE-5-inhibitor therapy for erectile dysfunction.
Corbin JD; Francis SH
J Androl; 2003; 24(6 Suppl):S38-41. PubMed ID: 14581493
[No Abstract] [Full Text] [Related]
6. The use of phosphodiesterase type 5 inhibitors for erectile dysfunction.
Montorsi F; Briganti A; Salonia A; Montorsi P; Rigatti P
Curr Opin Urol; 2004 Nov; 14(6):357-9. PubMed ID: 15626879
[No Abstract] [Full Text] [Related]
7. An update on the PDE-5 inhibitors (PDE-5i).
McCullough AR
J Androl; 2003; 24(6 Suppl):S52-8. PubMed ID: 14581496
[No Abstract] [Full Text] [Related]
8. [Erectile dysfunction: an update on new therapeutic options].
Roumeguère T
Acta Urol Belg; 2000; 68(2):41-2. PubMed ID: 11098588
[No Abstract] [Full Text] [Related]
9. [Erectile dysfunction and phosphodiesterase type 5 inhibitors].
Roumeguère T; Sternon J; Schulman CC
Rev Med Brux; 2003 Jun; 24(3):169-75. PubMed ID: 12891884
[TBL] [Abstract][Full Text] [Related]
10. Phosphodiesterase type 5 (PDE5) inhibitors.
Haning H; Niewöhner U; Bischoff E
Prog Med Chem; 2003; 41():249-306. PubMed ID: 12774696
[No Abstract] [Full Text] [Related]
11. [Levitra (vardenafil)--a new PDE 5 inhibitor for the treatment of erectile dysfunction].
Katsarov M
Akush Ginekol (Sofiia); 2004; 43 Suppl 1():31-2. PubMed ID: 15323315
[No Abstract] [Full Text] [Related]
12. Role of the cardiologist: clinical aspects of managing erectile dysfunction.
Hutter AM
Clin Cardiol; 2004 Apr; 27(4 Suppl 1):I3-7. PubMed ID: 15115189
[TBL] [Abstract][Full Text] [Related]
13. Tachyphylaxis and phosphodiesterase type 5 inhibitors.
Steers WD
J Urol; 2002 Jul; 168(1):207. PubMed ID: 12050542
[No Abstract] [Full Text] [Related]
14. New phosphodiesterase type 5 inhibitors in the management of erectile dysfunction.
Mason RG
J R Soc Promot Health; 2003 Jun; 123(2):79-80. PubMed ID: 12852189
[No Abstract] [Full Text] [Related]
15. [New PDE-5 inhibitor for treatment of impotence. 9 out of 10 have erections again].
MMW Fortschr Med; 2003 Jun; 145(26):59. PubMed ID: 12916343
[No Abstract] [Full Text] [Related]
16. [7 years PDE-5 inhibitor for therapy of erection disorders].
Krankenpfl J; 2005; 43(7-10):267. PubMed ID: 16518894
[No Abstract] [Full Text] [Related]
17. Tadalafil in the treatment of erectile dysfunction.
Bella AJ; Brock GB
Curr Urol Rep; 2003 Dec; 4(6):472-8. PubMed ID: 14622501
[TBL] [Abstract][Full Text] [Related]
18. Erectile dysfunction in the cardiac patient.
Kloner RA
Curr Urol Rep; 2003 Dec; 4(6):466-71. PubMed ID: 14622500
[TBL] [Abstract][Full Text] [Related]
19. Commentaries on Jackson et al. "Successful withdrawal of oral long-acting nitrates to facilitate phosphodiesterase type 5 inhibitor use in stable coronary disease patients with erectile dysfunction".
Kloner RA; Montorsi P; DeBusk RF
J Sex Med; 2005 Sep; 2(5):740-2; author reply 742. PubMed ID: 16422835
[No Abstract] [Full Text] [Related]
20. Phosphodiesterase-5 inhibitors: clinical market and basic science comparative studies.
McCullough A
Curr Urol Rep; 2004 Dec; 5(6):451-9. PubMed ID: 15541215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
